Daniel J. Lippis, the Corporate Vice President for JAPAC at Edwards Lifesciences Corp (NYSE:EW), has disclosed recent stock transactions in a regulatory filing. On January 16, Lippis sold 500 shares of Edwards Lifesciences common stock, netting approximately $34,382. The shares were sold at a weighted average price of $68.76, with the actual sale prices ranging from $68.42 to $69.07. The transaction comes as Edwards Lifesciences, currently valued at $41.3 billion, maintains a strong financial position with more cash than debt on its balance sheet, according to InvestingPro data.
Additionally, Lippis exercised options to acquire 500 shares of common stock at a price of $45.28 per share, totaling approximately $22,638. These transactions were conducted under a pre-established Rule 10b5-1 trading plan, which Lippis adopted on December 11, 2023. InvestingPro analysis suggests the stock is currently undervalued, with 7 additional ProTips available to subscribers, including detailed insights into management's share buyback activity and the company's financial health metrics.
Following these transactions, Lippis holds 23,189 shares of Edwards Lifesciences common stock. The company maintains strong profitability with a 76.6% gross margin and is expected to report its next earnings on January 30, 2024.
In other recent news, Edwards Lifesciences has been the focus of several analyst adjustments. Wolfe Research downgraded Edwards Lifesciences' stock rating to Underperform, citing concerns over the company's growth prospects. Despite this, the company reported impressive revenue growth of 24.02% in the last twelve months, as per InvestingPro data. Jefferies maintained a Hold rating on the company's stock, observing a year-over-year revenue decline of 2.7% for November 2024 in the U.S. TAVR market. However, fourth-quarter revenue growth was reported at 6.5%, surpassing the consensus estimate of 4% growth.
RBC (TSX:RY) Capital Markets projected a favorable outlook for the Medical (TASE:PMCN) Supplies & Devices sector for 2025, identifying significant upside opportunities in stocks such as Edwards Lifesciences. The firm's surveys indicate strong potential catalysts and market growth for the company, particularly in transcatheter valve therapies. BofA Securities upgraded Edwards Lifesciences from a Neutral to a Buy rating and increased the price target to $90 from the previous $82. The firm anticipates a positive trajectory for the company's stock in 2025, driven by multiple potential catalysts and the strategic importance of its TAVR technology.
Lastly, TD (TSX:TD) Cowen maintained a Hold rating on Edwards Lifesciences' stock after the company presented a favorable multiyear outlook. The company reiterated its 2024 guidance and introduced its 2025 projections, including a return to double-digit annual revenue growth and sustaining double-digit growth in earnings per share.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.